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ABSTRACT
Background: The increase in the incidence of allergic disorders especially in developed countries may be ex-
plained by the hygiene hypothesis. A novel therapeutic approach that causes a Th1-dominant response under
conditions of Th2-skewed immunity has been investigated. Mycobacterium bovis Bacillus Calmette-Guérin
(BCG) is a widely used anti-tuberculosis vaccine that strongly induces a Th1-predominant immune response. A
potential role for BCG in the treatment of allergic diseases has been reported. In the present study, we investi-
gated whether subcutaneous inoculation with a low dose (1 × 105) of BCG vaccine can attenuate allergic in-
flammation of the airway in a murine model of asthma.
Methods: Female BALBc mice were vaccinated on day 0 with a subcutaneous. injection of 1 × 105 CFU of
BCG, and sensitized to ovalbumin (OVA, i.p., with alum) on day 7 and 14, respectively. After a 2-week interval,
they were exposed to aerosolized OVA (1%). In another experiment, BCG-sensitized splenic CD4+ T cells were
adoptively transferred before sensitization.
Results: We found that BCG-vaccinated mice had fewer eosinophils in BALF and less severe allergic inflam-
mation. The expression of IL-4 as well as Eotaxin and TARC was down-regulated in the vaccinated mice, while
that of both IL-12 and IFN-γ was up-regulated. Moreover, the transfer of splenic CD4+ T cells from vaccinated
mice into naïve mice before OVA-sensitization prevented the development of allergic inflammation. These
splenic CD4+ T cells produced much IFN-γ.
Conclusions: The subcutaneous administration of (low-dose) BCG vaccine suppressed allergic inflammation
via Th1-skewed immunity and might have clinical applications in immunotherapy for asthma.
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INTRODUCTION
Epidemiological studies have proposed that the in-
crease in the prevalence of atopic diseases correlates
with a decrease in the incidence of infectious dis-
eases such as tuberculosis.1 This explanation has led
to the ‘hygiene hypothesis’, which suggests that the
increase in allergic diseases is caused by a cleaner
environment and fewer childhood infections. 2-4 A
number of reports support this hypothesis , demon-
strating that allergic disorders, like bronchial asthma,
have been increasing rapidly in developed countries
and favor Th2-skewed rather than Th1-skewed immu-
nity.5-10 It was believed that there is a reciprocal bal-
ance between Th1 cytokines including IFN-γ, TNF-α
and IL-12, and Th2 counterparts such as IL-4, IL-5
and IL-13. Th2 cytokines induce immunoglobulin (Ig)
E synthesis and eosinophilic inflammation, while Th1
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Fig. 1 Experimental design used to investigate the efect of BCG vaccine on OVA-
induced bronchial asthma. (a) Schematic representation of the experimental 
protocol. Mice were sensitized and chalenged as described in the Methods. Mice 
were treated with BCG or BCG-sensitized splenic CD4+ T cels before sensitization 
as indicated in the Methods. (b) Determination of BCG dose using the MTT assay. 
(c) Determination of BCG dose using DTH. Data are the means ± SEM from four 
mice in each group. *p＜0.05, **p＜0.01 compared with 1 × 104 CFU of BCG-im-
munized mice, control mice, respectively.
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cells, through the secretion of IL-12 and IFN-γ, play a
role in anti-mycobacterial immune responses by acti-
vating macrophages and protecting against allergic
diseases by dampening Th2 cytokine functions.11-13
Chemokines, which regulate the extravasation and
accumulation of leucocytes during immune and in-
flammatory responses, are involved in the pathogene-
sis of allergic disorders.14,15 For example, Eotaxin16,17
and TARC18 play a pivotal role in allergic inflamma-
tion of the airway. Some researchers reported that
vaccinations, such as measles19 , pertussis20 and tu-
berculosis,21,22 can cause a shift from a Th2 to Th1
milieu, which may protect against the development of
allergies. Mycobacterium bovis Bacillus Calmette-Gué
rin (BCG), a vaccine used to prevent tuberculosis, is
also reported to be a potent inducer of Th1-skewed
immunity.23 Some reports indicated that BCG treat-
ment suppresses allergen-induced inflammation of
the airway and hyperresponsiveness in mice . 24-27
However, in these previous studies, BCG (1 × 105―1 ×
107 CFU) was administered via the intranasal, intrave-
nous, or intraperitoneal route in mice.25-28 Normally,
BCG is inoculated subcutaneously at 107―108 CFU
human. In this study, we investigated whether BCG
subcutaneous (s.c.) vaccination with a lesser dose
(1 × 105 CFU) can inhibit allergic inflammation in-
duced by exposure to an allergen, change cytokine
production from a Th2 to Th1-dominant immune pro-
file, and regulate chemokines such as Eotaxin and
TARC. Possible roles of BCG vaccine in the develop-
ment of bronchial asthma are discussed.
METHODS
ANIMALS
Female BALBc mice, originally obtained from Shi-
zuoka Laboratory Animal Center (Shizuoka, Japan),
were maintained in our animal facility at Nara Medi-
cal University. Female 6-week-old mice were used for
experiments. All experimentation was conducted un-
der a protocol approved by our institutional review
board.
MYCOBACTERIUM (M.) BOVIS BCG
M. bovis BCG (Pasteur strain) was grown in Middle-
brook 7H9 broth (Difco, Detroit, MI, USA) supple-
mented with Middlebrook OADC enrichment (Life
Technologies, Gaithersburg, MD, USA) for 2 weeks
at 37℃. This strain was centrifuged at 8000 rpm for
30 minutes at 4℃ , and the precipitate was washed
with saline and stored frozen as 1 ml aliquots at −80℃
602 Allergology International Vol 54, No4, 2005 www.jsaweb.jp
Ito T et al.
Fig. 2 Efect of vaccination on the number of eosinophils 
recovered in the BALF. BALF was colected 48 hours after 
the final chalenge. Data are the means ± SEM from five 
mice in each group. The OVA-sensitized/chalenged mice 
vaccinated with BCG had significantly fewer eosinophils in 
the BALF (*p＜0.02). 
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Fig. 3 Histopathologic analysis of lung tissue. (a) OVA-
sensitized and PBS-exposed mice treated with vehicle 
(saline). (b) OVA-sensitized and PBS-exposed mice vacci-
nated with BCG. (c) OVA-sensitized and -exposed mice 
treated with vehicle. (d) OVA-sensitized and -exposed mice 
vaccinated with BCG. Histopathology showed accumulation 
of lymphocytes and eosinophils around airways and vessels 
and goblet cel hyperplasia in the lung tissue from OVA-sen-
sitized and -exposed mice in the vehicle control. These 
pathologic changes were reduced in the lung tissue from 
BCG-vaccinated mice. (e) Quantitative analysis of histopa-
thologic changes using a scoring system detailed in the 
methods. Data are the means ± SEM from five mice in 
each group. (p＜0.05). 
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prior to use. As for the concentration of BCG, the
number of colony forming units (CFU) per ml was
determined by dispersing the bacteria through expo-
sure to sonic oscillation and by plating suitable saline
dilutions on Middlebrook 7H10 agar medium.
3-(4,5-DIMETHYL-2-THIAZOLYL)-2,5-
DIPHENYLTETRAZOLIUM BROMIDE (MTT) AS-
SAY
The biological response of spleen lymphocytes was
evaluated using the 3-(4,5-Dimethyl-2-thiazolyl ) -2,5-
diphenyltetrazolium Bromide (MTT) assay (Nacalai
tesque Inc. Kyoto, Japan) according to the manufac-
turer’s instructions. Lymphocytes were obtained by
preparing single-cell suspensions from spleens of
mice 2 weeks after the BCG immunization. Cell sus-
pensions were passed through nylon mesh. RBC in
the spleen were lysed with an ammonium chloride so-
lution (ACK). These splenic lymphocytes (2 × 105)
were cultured with heat-killed BCG antigens (5 × 103)
or saline in 200 μl of RPMI 1640 medium containing
10% FCS and antibiotics in a round-bottomed 96-well
plate. All experiments were carried out in triplicate.
These cultures were incubated at 37℃ in a humidi-
fied 5% CO2 atmosphere for 72 hours. The cell viabil-
ity was >97% in dye exclusion tests using trypan blue.
MTT solution (10 μl) was added to each plate. After
90 minutes’ incubation at 37℃, the absorbance at 450
nm was read on a microplate reader.
DELAYED-TYPE HYPERSENSITIVITY (DTH)
DTH was evaluated using the footpad method .
Briefly, 10 μg of PPD in 10 μl of saline was injected
subcutaneously into the right hind footpad 20 days af-
ter the subcutaneous immunization of 1 × 104 or 1 ×
105 CFU of BCG in 200 μl of saline . Control mice
were injected with saline . After 48 hours , footpad
thickness was measured using a gauge micrometer
(Mitutoyo, Tokyo, Japan) and the difference in thick-
ness between the right and left hind footpads, the lat-
ter treated with saline alone as a control, was deter-
mined.
VACCINATION
Mice were vaccinated on day 0 with a s.c. injection of
1 × 105 CFU of BCG in 200 μl of saline . Non-
vaccinated control mice were injected only with sa-
line (Fig. 1a).
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Fig. 4 The efect of BCG vaccine on production of cytokines and chemokines. (a) 
RT-PCR analysis of the lung from each mice described in the Methods. (b) Levels 
of IFN-γ and IL-4 measured by ELISA in the serum of OVA-sensitized and -ex-
posed mice. Mice were treated with saline (□) or BCG (■). Data are the means ± 
SEM from five mice in each group (*p＜0.01).
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SENSITIZATION AND EXPOSURE TO THE AL-
LERGEN
BALBc mice were sensitized to ovalbumin (OVA) on
day 7 (20 μg with 2 mg of alum) and day 14 (10 μg
with 1 mg of alum) . After a 2-week interval , mice
were exposed to aerosolized OVA (1%, 10 minday,
for 3 consecutive days) or PBS (Fig. 1a).
BRONCHOALVEOLAR LAVAGE FLUID (BALF )
COLLECTION
At 48 hours after the final challenge , the animals
were euthanized with sodium pentobarbital (Nakalai
Tesque Inc . Kyoto , Japan ) . The chest wall was
opened and the animals were exsanguinated by car-
diac puncture . Serum was collected and stored at
−20℃ prior to use. The trachea was cannulated after
blood samples were collected. Bronchoalveolar lav-
age (BAL) was performed three times with 0.8 ml of
sterile PBS instilled and harvested gently . Lavage
fluid ( the volume recovered was −85% of that in-
stilled) was collected and 1 ml was centrifuged at
2000 rpm (400 g) for 10 minutes. The cell pellet was
resuspended in 0.25 ml of PBS. Total cell yield was
quantified by hemocytometer. Differential cell counts
were performed on cytocentrifuge slides prepared by
centrifugation of samples at 800 rpm for 5 minutes
(Autosmear CF12D, Sakura Seiki, Yao, Japan). These
slides were fixed in 95% methanol and stained with
Diff-Quick (Intl Reagent Corp, Kobe, Japan), modi-
fied Wright-Giemsa stain, and a total of 200 cells were
counted for each sample by microscopy . Macro-
phages , lymphocytes , neutrophils , and eosinophils
were enumerated.
HISTOLOGY
After lavage, some of the lungs were instilled with
10% buffered formalin , removed , and fixed in the
same solution. After paraffin embedding, sections for
microscopy were stained with H&E. An index of pa-
thologic changes in coded H&E slides was estab-
lished by scoring the inflammatory cell infiltrates
around airways and vessels for severity (0, normal; 1,
<3 cells thick; 2, 4―10 cells thick; 3, >10 cells thick)
and overall extent (0, normal; 1, <25% of sample; 2,
25―50%; 3, 51―75%; 4, >75%). The index was calculated
by multiplying severity by extent, with a maximal pos-
sible score of 12.
ISOLATION OF RNA AND RT-PCR ASSAY
Whole lungs were removed for the isolation of RNA
48 hours after the last administration of OVA. Total
RNA was isolated from whole lung using TRIZOL Re-
agent (Invitrogen Life Technologies, Carlsbad, CA,
USA) according to the manufacturer’s instructions. It
was then reversely transcribed into cDNA using a Su-
perscript II preamplification kit (Invitrogen Life Tech-
nologies) and amplified with specific oligonucleotide
primers as previously described.29 Primers specific
for β-actin ( forward 5 ’ -TGT GAT GGT GGG AAT
GGG TCA G-3’;reverse 5’-TTT GAT GTC ACG CAC
GAT TTC C-3’), IFN-γ (forward 5’ -ACT GCC ACG
GCA CAG TCA-3’ ; reverse 5’ -GCG ACT CCT TTT
CCG CTT-3’), IL-4 (forward 5’-GAA TGT ACC AGG
AGC CAT ATC C-3’; reverse 5’-AAT CCA TTT GCA
TGA TGC TCT T-3’), IL-12 (forward 5’ - GAT GAC
ATC ACC TGG ACC TCA-3’; reverse 5’ - TCC TTC
TTG TGG AGC AGC AG-3’), Eotaxin (forward 5’-AGA
GCT CCA CAG CGC TTC TAT T-3’; reverse 5’-GGT
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Fig. 5 Efect of BCG-sensitized CD4＋ T cels on the num-
ber of eosinophils recovered in the BALF. At 14 days after 
the inoculation with BCG (1 × 105 CFU, s.c.) or saline, 
splenic CD4＋ T cels (2 × 106) were adoptively transfered 
to naïve BALB/c mice via a tail vein. From the folowing day, 
sensitization and exposure to the alergen were performed. 
Adoptive transfer of BCG-sensitized CD4＋ T cels signifi-
cantly reduced the number of eosinophils in BALF in OVA-
sensitized and -exposed mice. Data are the means ± SEM 
from five mice in each group (*p＜0.02, **p＜0.01). 
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GCA TCT GTT GTT GGT GAT T-3’), and TARC (for-
ward 5’- CAG GAA GTT GGT GAG CTG GTA TA-3’;
reverse 5’- TTG TGT TCG CCT GTA GTG CAT A-3’)
were designed and synthesized at the Japan Bio Serv-
ices (Saitama, Japan). PCR was performed for 35 cy-
cles of 94℃ for 30 seconds, 58℃ for 45 seconds, and
72℃ for 45 seconds, with the final extension done at
72℃ for 10 minutes. The PCR products were exam-
ined by 2.5% agarose gel electrophoresis.
ADOPTIVE CD4+ T CELL TRANSFER EXPERI-
MENT
Fourteen days after the inoculation of BCG (1 × 105
CFU, s.c.) or saline, the entire spleen was removed.
Following the lysis of RBC with ACK, splenic CD4+ T
cells were isolated magnetically after incubation with
anti-mouse CD4 (L3T4) mAb-coated magnetic beads
(MACS; Miltenyi Biotec, Auburn, CA, USA). Cell pu-
rity was more than 95% throughout the experiments.
These splenic CD4+ T cells (2 × 106) were adoptively
transferred to naïve BALBc mice via a tail vein .
From the following day, sensitization and exposure to
the allergen were performed. At 48 hours after the
last exposure, mice were sacrificed for pathological
analysis of the lungs (Fig. 1a).
CELL CULTURE
Isolated CD4+ T cells (2 × 105) were cultured in tripli-
cate with heat-killed BCG (5 × 103) or saline in 200 μl
of RPMI 1640 medium containing 10% FCS and antibi-
otics in a round-bottomed 96-well plate as described.
These cultures were incubated at 37℃ in a humidi-
fied 5% CO2 atmosphere. The culture supernatants for
cytokine analysis were harvested 72 hours after cul-
ture and stored at −20℃ prior to use.
CYTOKINE ELISA
The total amounts of IFN-γ and IL-4 in the serum and
culture supernatant were measured by ELISA. ELI-
SAs for IFN-γ and IL-4 were conducted according to
the manufacturer’s recommendations (Pierce Endo-
gen, Rockford, IL). Standard curves were obtained
using the standard samples provided. The sensitivity
for each assay was 5 pgml.
STATISTICAL ANALYSIS
Statistical analysis was performed using Student’s t-
test. The 95% confidence limit was taken as signifi-
cant. Results are expressed as means ± S.E.M. (n = 4―
5)
RESULTS
DETERMINATION OF BCG DOSE
To determine the appropriate dosage of BCG for im-
munization , we used the MTT assay and footpad
method. In the MTT assay, there was a significant dif-
ference in proliferative response to 1 × 105 CFU and
1 × 104 CFU or 1 × 103 CFU of BCG (Fig. 1b). More-
over , the mice that received 1 × 105 CFU of BCG
showed a significant difference in footpad thickness
compared with the control mice (Fig. 1c). Accord-
ingly, we selected a dosage of 1 × 105 CFU for the
vaccination.
CELLULAR PROFILES IN THE BALF
To quantitatively evaluate the cellular responses to
the vaccination, we examined the cellular profiles in
BALF . OVA-sensitized and exposed mice had in-
creased eosinophil numbers in BALF compared with
control mice sensitized to OVA and exposed to PBS.
The vaccination significantly decreased the number
of eosinophils in BALF (29.4 ± 12.5 × 104 vs. 10.9 ±
5.4 × 104ml, p < 0.02) (Fig. 2).
HISTOPATHOLOGY OF LUNG TISSUE
To examine responses, a histological assessment of
lung tissue from mice sacrificed at 48 hours after the
last challenge was conducted. The mice showed ro-
bust pathologic changes due to allergic inflammation
(eosinophil and mononuclear cell infiltration around
the airway and vessels and goblet cell hyperplasia)
(Fig. 3a). Histological evaluation of the lungs re-
vealed a dampening of the pulmonary inflammation in
the vaccinated mice (Fig. 3a). The OVA-sensitized
challenged mice that received the BCG vaccine
showed significantly less cellular infiltration and gob-
let cell hyperplasia (2.93 ± 0.49 vs. 1.38 ± 0.27, p <
0.05) (Fig. 3b).
Allergology International Vol 54, No4, 2005 www.jsaweb.jp 605
The Effect of BCG Vaccine on Asthma
Fig. 6 Histopathologic analysis of lung tissue. PBS only (a), splenic CD4＋ T cels from 
non-immunized mice (b), or splenic CD4＋ T cels from vaccinated mice (c) were adop-
tively transfered to naïve BALB/c mice via a tail vein. They were sensitized and exposed 
to OVA as described in the Methods. The transfer of BCG-sensitized CD4＋ T cels caused 
less extensive pathologic change in OVA-sensitized and -exposed mice (d) Histopatho-
logic scoring is detailed in the Methods. Data are the means ± SEM from five mice in each 
group (*p＜0.05, **p＜0.01). 
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EFFECT OF VACCINATION ON CYTOKINE AND
CHEMOKINE PRODUCTION
To elucidate the mechanism by which allergic inflam-
mation is inhibited by the vaccination , a RT-PCR-
based analysis of whole lungs was performed. IL-4,
Eotaxin and TARC gene expression levels were sig-
nificantly lower in vaccinatedOVA-challenged mice
than in non-vaccinatedOVA-challenged mice, while
IL-12 and IFN-γ gene expression was upregulated af-
ter the vaccination regardless of exposure to OVA
(Fig. 4a). Mice that received the BCG vaccine also
showed higher levels of IFN-γ in serum (37.01 ± 16.25
vs. 126.0 ± 45.05 pgml, p < 0.01). On the other hand,
there was no significant difference in IL-4 production
(Fig. 4b). These results suggest that BCG vaccination
stimulates the shift to a Th1 environment.
EFFECTS OF CD4+ T CELLS
To investigate whether helper CD4+ T cells , espe-
cially Th-1 cells, helped to attenuate allergic inflam-
mation of the airway, splenic CD4+ T cells from the
vaccinated mice were transferred into naïve mice be-
fore OVA-sensitization. Control mice received naïve
CD4+ T cells or PBS only . The transfer of BCG-
sensitized CD4+ T cells significantly reduced eosino-
phil numbers in BAL fluid in OVA-sensitized and
-exposed mice (PBS, naïve CD4+ T cells, and BCG-
sensitized CD4+ T cells; 33.7 ± 9.63 × 104, 25.7 ± 14.3 ×
104, and 5.13 ± 3.65 × 104ml, respectively) (p < 0.01
vs. PBS, and p < 0.02 vs. naïve CD4+ T cells) (Fig. 5),
and diminished the pathogenic changes of allergic in-
flammation (Fig. 6a). The histological score also de-
creased significantly on the transfer of BCG-
sensitized CD4+ T cells. The score was 3.10 ± 0.69
(p < 0.01), 2.02 ± 0.24 (p < 0.05), and 0.54 ± 0.32, re-
spectively (Fig. 6b). IFN-γ gene expression was sig-
nificantly higher , while IL-4 gene expression was
lower with BCG-sensitized CD4+ T cells than non-
sensitized CD4+ T cells, (Fig. 7a). Moreover, a much
larger amount of IFN-γ was produced on the transfer
of BCG-sensitized CD4+ T cells (92.4 ± 14.9 vs. 9556 ±
1819 pgml, p < 0.01) (Fig . 7b). IL-4 was undetect-
able.
DISCUSSION
The present study demonstrated that an inoculation
of BCG vaccine was effective in reducing allergic in-
flammation of the airway in an OVA-sensitized
murine model of asthma. Previous studies support
the hypothesis that BCG immunization can promote
Th1 immunity,30 which has the potential to inhibit al-
lergic disorders by attenuating Th2 immunity.31 How-
ever, the mechanism by which mycobacteria, such as
BCG and M. vaccae , inhibit the inflammatory re-
sponse has not been fully elucidated though various
mechanisms have been proposed.24-28,32-34 Although
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Fig. 7 The efect of BCG vaccine on splenic CD4＋ T cels. (a) RT-PCR analysis of 
splenic CD4＋ T cels obtained from saline- or BCG-injected mice. (b) Levels of IFN-γ meas-
ured by ELISA in the culture supernatants of splenic CD4＋ T cels from saline- or BCG-in-
oculated mice. Data are the means ± SEM from four mice in each group (*p＜0.01).
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the BCG vaccine is used clinically, few studies have
demonstrated that subcutaneous inoculation with
BCG suppresses allergic inflammation of the airway
in OVA-sensitized mice. The potential to inhibit in-
flammatory responses was much lower in subcutane-
ously immunized mice than in mice that were immu-
nized via the intranasal , intravenous or intraperito-
neal route.25,35
We selected 1 × 105 CFU as the dosage of BCG for
this study, based on the difference in weight between
mice (6 week) and neonatal human infants, who are
vaccinated subcutaneously with 107― 108 CFU of
BCG.21,36 Moreover, even a low dose of BCG vaccine
caused a Th-1 dominant response in spite of the fact
that BALBc mice have a genetic Th2 bias. Acosta et
al. conducted a histopathologic study of BALBc
mice inoculated with BCG (1 × 106 CFU) by different
routes, oral, intravenous and subcutaneous.37 When
the subcutaneous route was used, granuloma lesions
developed only at the site of inoculation , whereas
there was systemic dissemination when the oral or in-
travenous route, especially the latter, was employed.
Realistically, the administration of BCG orally and in-
travenously, including the intraperitoneal and intrana-
sal routes, is not practical because of the risk of infec-
tion. Our results might contribute directly to immu-
notherapy. In this study, we demonstrated that vacci-
nation with BCG in OVA-sensitized mice significantly
inhibited allergic inflammation of the airway and the
effect was caused by BCG-sensitized CD4+ T cells .
These cells produced large amounts of IFN-γ , and
might change cytokine profiles from a Th2 to Th1-
type immunity. Some reports demonstrated that IFN-
γ gene transfer inhibited allergic inflammation , 38,39
and that this effect was dependent on the IL-12 and
STAT4 signaling pathways.40 RT-PCR analysis dem-
onstrated a high-level of gene expression of IFN-γ in
CD4+ T cells from BCG-vaccinated mice. However ,
there was no significant difference in IL-4 levels in
sera between the PBS and OVA exposed group .
These findings indicate that exposure to OVA might
change the Th1Th2 balance in the lung, but not in
the systemic circulation . Zuany-Amorim et al. sug-
gested that regulatory T cells generated by mycobac-
teria treatment had the potential to suppress inflam-
mation of the airway through the subcutaneous injec-
tion of Mycobacterial Ags, M. vaccae, and did not al-
ter IL-4 levels in BAL fluid.41 In a recent study, adop-
tive transfer of Th-1-like regulatory T cells markedly
reduced the development of allergic inflammation.42
The involvement of a mechanism other than simple
changes in the balance between Th1 and Th2 was
suggested.
Chemokines, a group of specialized cytokines, play
essential roles in the recruitment of leukocytes to
sites of inflammation.43 For example, Eotaxin which
is thought to play an important role in the recruit-
ment of eosinophils to airways and TARC, a selective
chemoattractant of Th2 cells, is a reasonable candi-
date for a key regulator of Th2-mediated inflamma-
tion in allergic asthma . 44-46 Our data revealed that
gene expression of TARC as well as Eotaxin in the
lung was down-regulated by the vaccination . How-
ever, the mechanism by which the BCG vaccine in-
hibited these chemokines is still unknown. Accord-
ingly, further investigations on regulatory T cells and
chemokines are needed.
In conclusion, we demonstrated that the subcuta-
neous inoculation of low dose BCG vaccine attenu-
ated allergic inflammation of the airway in BALBc
mice. The expression of IL-4 as well as Eotaxin and
TARC was down-regulated in the vaccinated mice ,
while that of IL-12 and IFN-γ was up-regulated. More-
over, the transfer of splenic CD4+ T cells, which pro-
duced a large amount of IFN-γ, prevented the devel-
opment of allergic inflammation. The BCG vaccine
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could potentially be used for immunomodulation in
the treatment and prevention of bronchial asthma.
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